|
New Leaf Ventures (NLV) employs a differentiated investment
strategy that has been employed and refined since 1993. Our
latest funds, New Leaf Ventures I and New Leaf Ventures II, both focus on
taking leadership positions in financings of:
-
Later stage biopharmaceuticals – NLV has
an in-depth understanding of drug development, clinical trial
design, and pharmaceutical markets. We bring our medical,
clinical development, commercial, and financial experience to
bear to help companies succeed in bringing products to market
and then commercializing.
-
Medical devices, generally at early stages
– NLV partners have an extensive network of
entrepreneurs and scientific or medical founders, an ability to
evaluate biological, engineering, and market risks, and the
operating experience to help build these companies and create
the best exit opportunities. The NLV team has a successful
history of helping entrepreneurs fund new companies, and we
frequently sponsor Entrepreneurs-in-Residence and help them find
partners and ideas on which to base new companies.
-
Molecular Diagnostics and laboratory infrastructure at a variety of
stages – The NLV team brings an understanding of
the science and technology underlying modern diagnostics and
laboratory processes, insight into where real market
opportunities exist and can be exploited, and the experience to
grow such businesses. The NLV team is distinctive in its focus,
experience and track record in this subsector. When most of the
venture community disdained diagnostics, we were actively
building successful companies in this sector.
In addition to providing attractive risk-return
opportunities, this combination of strategies creates
diversification across healthcare sectors, across development
stages, and across the private and public markets.
|
